Sebetralstat

Sebetralstat
Clinical data
Trade names	Ekterly
Other names	KVD-900, KVD900
AHFS/Drugs.com	Monograph
MedlinePlus	a625087
License data	US DailyMed: Sebetralstat;
Routes of; administration	By mouth
Drug class	Plasma kallikrein inhibitor
ATC code	B06AC08 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-[[4-[(2-oxopyridin-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxamide;
CAS Number	1933514-13-6;
PubChem CID	121365142;
IUPHAR/BPS	11947;
DrugBank	DB18305;
ChemSpider	115006749;
UNII	O5ZD2TU2B7;
KEGG	D12396;
ChEMBL	ChEMBL5095248;
Chemical and physical data
Formula	C26H26FN5O4
Molar mass	491.523 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COCC1=NN(C=C1C(=O)NCC2=NC=CC(=C2F)OC)CC3=CC=C(C=C3)CN4C=CC=CC4=O;
	InChI InChI=1S/C26H26FN5O4/c1-35-17-22-20(26(34)29-13-21-25(27)23(36-2)10-11-28-21)16-32(30-22)15-19-8-6-18(7-9-19)14-31-12-4-3-5-24(31)33/h3-12,16H,13-15,17H2,1-2H3,(H,29,34); Key:KGMPDQIYDKKXRD-UHFFFAOYSA-N;

Sebetralstat, sold under the brand name Ekterly, is a medication used for the treatment of hereditary angioedema. Sebetralstat is a plasma kallikrein inhibitor that suppresses the activation of the positive feedback mechanism of the kallikrein-kinin system, thereby reducing factor XIIa and additional plasma kallikrein production. By inhibiting plasma kallikrein, sebetralstat reduces the production of bradykinin, thereby halting the progression of hereditary angioedema attacks. It is taken by mouth.

The most common side effect is headache.

Sebetralstat was approved for medical use in the United States in July 2025, and in the European Union in September 2025.